Scott Naisbitt

Curon Medical, Inc. develops, manufactures and markets proprietary products for the treatment of gastrointestinal disorders. Its products consist of radiofrequency generators and single-use disposable devices. The company was founded on May 1, 1997 and is headquartered in Fremont, CA.

Data Sciences International, Inc. offers telemetry instrumentation and software and services in support of research. Its services include data services, surgical services, validation services and technical training. The firm’s products include implantable and external telemetry, software, signal conditioners, glucose monitoring, infusion pumps and inhalation/exposure systems. The company was founded by Brian P. Brockway in 1984 and is headquartered in St. Paul, MN.

Velocimed LLC develops, manufactures, and markets medical devices. The firm's products are used in cardiology and neurology applications. The company was founded in 2001 by Jay Schmelter, Michael Berman, and Dennis W. Wahr and is headquartered in Maple Grove, MN.

UltraShape, Inc. manufactures and markets non-invasive devices for the aesthetic medical field. The company was founded by Betsy S. Atkins and Glicksman Ami in 2000 and is headquartered in San Ramon, CA.

BeneChill, Inc. develops non-invasive cooling technology for cerebral ischemia treatment. The company was founded by Michael L. Berman and Denise Barbut in 2004 is headquartered in San Diego, CA.

InterValve, Inc. operates as a medical device company which develops aortic valvuloplasty balloons for treatment of calcific aortic stenosis. Its V8 product is enhanced with leaflet hyperextension without increasing the risk of annulus over-distension. The firm also develops tools for the percutaneous and trans-apical aortic valve replacement procedure. The company was founded by Wes Pedersen, Mark Ungs, Robert S. Schwartz and Robert A. Van Tassel in 2008 and is headquartered in Plymouth, MN.

Rebiotix, Inc. develops and commercializes medical therapies. It offers human microbiome, clostridium difficile, inflammatory bowel disease or ulcerative colitis, hepatic encephalopathy, multi-drug resistant organism, and microbiota restoration therapies. The company was founded by Lee A. Jones, Michael Berman, and Erwin A. Kelen in 2011 and is headquartered in Roseville, MN.

Avalyn Pharma, Inc. manufactures pharmaceutical products. It develops improved therapies for the treatment of idiopathic pulmonary fibrosis (IPF) and other severe respiratory diseases. The company was founded by Richard Glenn Vincent and Mark W. Surber in 2011 and is headquartered in Seattle, WA.

Lyric Pharmaceuticals, Inc. operates as a clinical-stage pharmaceutical company. The firm develops novel gastrointestinal therapeutics for unmet medical needs in the hospital settings. The company was founded by David Wurtman and M. Scott Harris in 2013 and is headquartered in South San Fancisco, CA.

Cornell University is an educational institution that offers undergraduate and post graduate programs. It was founded in 1865 and is based in Ithaca, NY.

Bridgepoint Medical, Inc. develops interventional technology in the field of cardiology. It focuses on developing innovative and proprietary technology in the field of interventional cardiology for access to and treatment of chronic total occlusions. The company was founded by Michael L. Berman, Chad J Kugler and Robert E Atkinson in 2005 and is headquartered in Plymouth, MN.

BioEnterprise Corp. provides access to capital through both its relationships with venture capital and investment banking firms. It initiates for start up funding, and networking information, recruitment, and emerging support firms, including medical devices companies. The company was founded in 2002 and is headquartered in Cleveland, OH.

Excaliard Pharmaceuticals, Inc. manufactures, develops therapeutics for the treatment of scarring and fibrotic disorders. The company was founded by John Gordon Foulkes and Nicholas M. Dean in 2006 and is headquartered in New York, NY.

Lutonix, Inc. develops and commercializes drug coated balloon catheters. Its catheters help to deliver therapeutic dose of paclitaxel. The firm’s catheters are used to treat peripheral and coronary lesions. The company was founded in July 2007 by Dennis Wahr and Lixiao Wang and is headquartered in New Hope, MN.

Amplyx Pharmaceuticals, Inc. develops broad-spectrum antifungal agents for the treatment of life-threatening fungal infections. The firm's compound APX001, shows broad-spectrum activity in animal models of invasive fungal infection by common species of Candida and Aspergillus. It develops oral and injectable anti-infective drugs, including protease inhibitors and antibiotics. The company was founded by André Marquis, Mitchell W. Mutz and Gerry Crabtree in 2006 and is headquartered in San Diego, CA.

UltraShape redefines aesthetic medicine by developing, manufacturing and marketing innovative non-invasive technologies for fat cell destruction and body sculpting. The company develops and markets clinically proven safe and effective solutions that enhance the lives of patients. The UltraShape proprietary technology employs pulsed (non-thermal) focused ultrasound that instantly, selectively and permanently destroys fat cells without affecting surrounding structures. Founded in 2000, UltraShape has sold Contour I devices in more than 50 countries, demonstrating safety and efficacy. The UltraShape Contour I system, is authorized for marketing outside the U.S. It is the first clinically proven non-invasive solution that offers measurable lasting body sculpting results for men and women with no need for maintenance treatments. The UltraShape system has been shown to be safe and effective in a multi-center controlled trial and numerous other peer-reviewed published independent clinical studies. The device is designed to produce mechanical, non-thermal, acoustic effects which target and selectively destroy (breakdown) fat cells, leaving surrounding critical structures such as skin, blood vessels, nerves, and connective tissue intact. The latest Contour I V3 system uses Vertical Dynamic Focus™ (VDF) pulsed (non-thermal) focused ultrasound that instantly and permanently destroys fat cells providing patients a convenient noninvasive no-downtime solution to reduce localized fat deposits and body circumference. The UltraShape procedure is based on a natural fat clearance process where triglycerides and cell debris from the destroyed fat cells are processed by the body's natural physiological and metabolic pathways. These pathways are the same that handle fat during weight loss. Results from UltraShape's peer-reviewed published multi-center controlled clinical trial and other independent clinical studies show that the released triglycerides do not accumulate to a clinically significant extent in the blood or liver. Over 200,000 patient treatments have been performed worldwide with the Contour I showing high patient satisfaction while demonstrating safety and efficacy. The UltraShape procedure is guided by proprietary real-time tracking and guidance technology designed to deliver smooth, uniform body contouring results. The software guides the operator through a pres-determined treatment algorithm designed to minimize risk of contour irregularities, a common side effect of invasive and non-invasive procedures. The UltraShape procedure is performed during a convenient, 'walk-in, walk-out' session carried out in an office-based environment; it requires no anesthesia or sedation. After treatment, patients immediately resume their daily routines with no need for maintenance treatments. The UltraShape Contour I received the CE Mark in 2005 and a medical device license from Health Canada in 2007. The Contour I system is not available for sale in the U.S; the Contour Plus system is an investigational product limited by U.S. law to investigational use only.

Pharmacentra LLC provides marketing and communications programs for the pharmaceutical and insurance industries. The private company is based in Norcross, GA. The CEO of the company is Dan Berman.

EndoSpan Ltd. develops novel endovascular system for endovascular aortic aneurysm repair. The firm is opening up options for repairing aneurysms and dissections in patients with anatomy previously unsuitable for endovascular therapy. The company was founded by Rafi Benary and Alon Shalev in 2009 and is headquartered in Herzlia, Israel.

Ziarco Group Ltd. operates as a clinical-stage biotechnology company that develops therapeutics targeting inflammatory skin diseases. The firm engages in development of novel treatments in dermatology. The company was incorporated on March 10, 2014 and is headquartered in Canterbury, the United Kingdom.

SoniVie Ltd. engages in the development of a system for the treatment of pulmonary hypertension. Its products include Therapeutic Intra-Vascular Ultrasound (TIVUS) system, an intravascular, catheter-based technology that can cause denervation of nerves surrounding blood vessels and other structures like the bronchus. The company was founded by Moshe Arkin in 2014 and is headquartered in Rosh Haayin, Israel.

PulmOne Advanced Medical Devices Ltd. develops devices designed to allow lung function testing. It manufactures and distributes the MiniBox, an office based solution providing complete lung function testing in a portable device. The company was founded by Avi Lazar in 2006 and is headquartered in Raanana, Israel.

Part of Medtronic Plc, Mazor Robotics LLC is a company that specializes in the Mazor X Stealth Edition robotic guidance platform. The company is based in Orlando, FL. The platform is equipped with advanced software, robotic technologies, navigation, and instrumentation to support predictable surgical procedures. Christopher Prentice has been the CEO of the company since 2014.

Glycomine, Inc. engages in the development of therapeutics for diseases which have no treatment options. Its therapeutic approach is to combine replacement therapies such as substrates, enzymes, or proteins with intracellular delivery vehicles consisting of bio-nanomaterials or ligands that target the molecules to the cell interior of clinically relevant organs. It focuses on research of mannose-1-phosphate and Ngly1 enzyme replacement therapy, and observational study of GLY-000. The company was founded in 2014 by Agnes Rafalko and is headquartered in San Carlos, CA.

VentureMed Group, Inc. designs, develops, and markets interventional devices for the treatment of peripheral artery disease. Its product platforms are designes to reduce procedural costs and improve clinical outcomes. The company was founded by John P. Pigott in 2012 and is headquartered in Plymouth, MN.

Vensana Capital Management LLC (Vensana Capital) is a venture capital and growth equity investment firm founded in 2019 by Peter Klein Justin & Kirk G. Nielsen. The firm is headquartered in Saint Paul, Minnesota.

Curzion Pharmaceuticals, Inc. operates as a pharmaceutical firm. The company is headquartered in San Diego, CA.

Sparrow Pharmaceuticals, Inc. engages in pharmaceuticals industry. It develops drugs for cushing?s syndrome. The company was founded by David A. Katz and is headquartered in Portland, OR.